8-K: Larimar Advances FA Drug, Boosts Cash to Q4 2026

Larimar Therapeutics reported Q2 2025 financial results and provided key updates on its nomlabofusp program for Friedreich's ataxia, including a strengthened cash position and clear regulatory path.

Summary

• Larimar Therapeutics announced Q2 2025 financial results and operational highlights for its nomlabofusp program for Friedreich's ataxia (FA).
• The company had $138.5 million in cash, cash equivalents, and marketable securities as of June 30, 2025.
• Pro forma cash, including $65.1 million in net proceeds from a July 2025 public offering, totals $203.6 million, extending the projected cash runway into the fourth quarter of 2026.
• Net loss for Q2 2025 was $26.2 million, or $0.41 per share, compared to a net loss of $21.6 million, or $0.34 per share, for Q2 2024.
• Research and development expenses increased to $23.4 million in Q2 2025 from $19.7 million in Q2 2024, driven by clinical trial activities, personnel costs, and confirmatory study design.
• General and administrative expenses decreased to $4.4 million in Q2 2025 from $4.9 million in Q2 2024.
• The FDA has provided written recommendations for key elements of the Biologics License Application (BLA) submission, including safety database requirements (at least 30 participants for 6 months, 10 for 1 year, mostly on 50 mg dose) and openness to using skin frataxin (FXN) concentrations as a reasonably likely surrogate endpoint (RLSE).
• Initial data from the 50 mg dose in the open label study and data from the adolescent pharmacokinetic (PK) run-in study are expected in September 2025.
• The BLA seeking accelerated approval for nomlabofusp is on track for submission in the second quarter of 2026, with a U.S. launch planned for early 2027.
• Global Phase 3 study sites have been identified and are being qualified, with patient recruitment expected to initiate later this year.
• The company published two peer-reviewed articles on nonclinical data supporting nomlabofusp's mechanism of action and the use of skin FXN concentrations as a RLSE.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to clear regulatory progress with FDA alignment on accelerated approval pathways and surrogate endpoints, upcoming significant clinical data readouts, and a strengthened financial position extending the cash runway. While losses increased, this is expected for a clinical-stage biotech advancing a late-stage program. The overall outlook for nomlabofusp's development and potential market entry is strong.

Positives

• Strengthened balance sheet with $203.6 million in pro forma cash, providing a projected cash runway into Q4 2026.
• Clear regulatory path established with written FDA recommendations for BLA submission, including acceptance of skin FXN concentrations as a reasonably likely surrogate endpoint for accelerated approval.
• Key clinical data readouts for the 50 mg open label study and adolescent PK run-in study are expected in September 2025, serving as near-term catalysts.
• BLA submission for accelerated approval is on track for Q2 2026, positioning nomlabofusp as the first potential disease-modifying therapy for Friedreich's ataxia.
• Global Phase 3 study sites identified and patient recruitment expected to begin later this year, advancing the confirmatory study.
• Successful transition to the lyophilized formulation of nomlabofusp, intended for commercialization, in the open label study.
• Nonclinical data supporting the mechanism of action and surrogate endpoint published in two peer-reviewed articles, reinforcing scientific credibility.

Negatives

• Increased net loss for Q2 2025 ($26.2 million) compared to Q2 2024 ($21.6 million), and for the six months ended June 30, 2025 ($55.5 million) compared to the same period in 2024 ($36.3 million).
• Higher research and development expenses due to increased clinical trial activity, personnel costs, and initial activities for the planned confirmatory study.

Risks

• The success, cost, and timing of product development activities, nonclinical studies, and clinical trials, including nomlabofusp clinical milestones and continued interactions with the FDA.
• Preliminary clinical trial results may differ from final clinical trial results, and earlier non-clinical and clinical data may not be predictive of the results or success of later trials.
• The FDA may not ultimately agree with Larimar's nomlabofusp development strategy or the acceptability of skin FXN increases for accelerated approval during future BLA review.
• Potential impact of public health crises on future clinical trials, manufacturing, regulatory, nonclinical study timelines, operations, and general economic conditions.
• Ability to optimize and scale nomlabofusp's manufacturing process, including reliance on third-party manufacturers.
• Ability to obtain regulatory approvals for nomlabofusp and future product candidates.
• Ability to develop sales and marketing capabilities, alone or with collaborators, and successfully commercialize any approved product candidates.
• Ability to raise the necessary capital to conduct product development activities beyond the current projected cash runway.
• Delays in patient recruitment, including as a result of changes in clinical protocols and adverse events.
• Anaphylaxis has been deemed an adverse drug reaction likely related to nomlabofusp, particularly in participants with prior exposure who have been off treatment for some time.

Future Outlook

Larimar Therapeutics plans to submit a Biologics License Application (BLA) seeking accelerated approval for nomlabofusp in the second quarter of 2026, with a U.S. launch anticipated in early 2027. The company expects to initiate patient recruitment for its global Phase 3 study later this year. Initial data from the 50 mg dose in the open label study and the adolescent PK run-in study are expected in September 2025. The projected cash runway extends into the fourth quarter of 2026.

Management Comments

• "We are pleased with our continued strong execution as we further advance our nomlabofusp program towards potential registration."
• "Importantly, we have written communications in hand from the Food and Drug Administration (FDA) for key elements of our Biologics License Application (BLA) submission including safety database recommendations and a potential accelerated approval pathway based on the use of skin frataxin levels as a novel surrogate endpoint."
• "We also recently published two peer-reviewed papers, including nonclinical data contributing to the FDAs openness to using skin frataxin (FXN) concentrations as a reasonably likely surrogate endpoint (RLSE)."
• "Enrollment in our open label study is ongoing, and new study participants are now receiving the lyophilized formulation of nomlabofusp."
• "We have several important near-term catalysts ahead including initial data from the 50 mg dose of our open label study and data from the adolescent pharmacokinetic (PK) run-in study expected in September 2025."
• "Global sites have been identified for our Phase 3 trial, and we expect to initiate patient recruitment later this year."
• "With our balance sheet strengthened through our recent capital raise, key clinical data approaching, and a clear regulatory path in place, we are well-positioned to submit our BLA for nomlabofusp in the second quarter of 2026 as the first potential disease modifying therapy for Friedreichs ataxia (FA)."

Industry Context

Friedreich's ataxia (FA) is a rare, progressive neurodegenerative disease affecting approximately 20,000 patients globally, with about 5,000 in the U.S. It is characterized by a genetic defect leading to insufficient frataxin (FXN) levels, causing symptoms like unsteady posture, frequent falling, and eventually wheelchair confinement, with a life expectancy of 30-50 years often due to heart disease. The only currently approved treatment, Biogen's Omaveloxolone (SKYCLARYS), does not address the underlying frataxin deficiency. Larimar's nomlabofusp is positioned as the first potential disease-modifying therapy designed to directly address this fundamental FXN deficiency, representing a significant unmet medical need in the FA treatment landscape.

Comparison to Industry Standards

• Nomlabofusp is designed as a protein replacement therapy, directly addressing the underlying frataxin deficiency in FA, which differentiates it from Biogen's approved Omaveloxolone (SKYCLARYS), an Nrf2 Activator that does not directly replace frataxin.
• Preclinical data for nomlabofusp demonstrates significant efficacy in mouse models of FA, including extending survival, preventing ataxic gait, delivering human frataxin to mitochondria, restoring succinate dehydrogenase (SDH) activity, and preserving left ventricle function, which are critical indicators for a disease impacting cardiac and neurological systems.
• The FDA's openness to using skin frataxin concentrations as a 'reasonably likely surrogate endpoint' (RLSE) for accelerated approval is a notable regulatory alignment, potentially expediting market access compared to traditional clinical endpoints.
• The company's robust intellectual property portfolio, including composition of matter patents extending into 2040 and eligibility for 12 years of market exclusivity in the US and 10 years in the EU upon approval, provides a strong competitive advantage in the rare disease space.

Stakeholder Impact

• **Shareholders:** Positive impact due to clear regulatory pathway, upcoming data catalysts, extended cash runway, and potential for accelerated approval and market entry of a first-in-class therapy, which could drive significant value.
• **Patients with Friedreich's Ataxia (FA):** Highly positive impact as nomlabofusp aims to be the first disease-modifying therapy directly addressing the underlying cause of FA, offering hope for improved outcomes and quality of life. The expansion of the open label study to include adolescents and children is also beneficial.
• **Employees:** Positive impact due to continued progress in clinical development, BLA preparation, and a strengthened financial position, indicating job security and growth opportunities within the company.
• **Regulatory Authorities (FDA, EMA, MHRA):** Continued collaboration and adherence to regulatory guidance, as evidenced by written FDA recommendations and participation in the START pilot program, fostering a constructive relationship.
• **Healthcare Providers/Researchers:** Potential for a new, effective treatment option for FA, which could change clinical practice and provide a valuable tool for managing the disease.

Next Steps

• Provide an update on open label data for at least 30 to 40 study participants who received at least one dose of nomlabofusp in September 2025.
• Release safety and PK data from the adolescent PK run-in study in September 2025.
• Initiate patient recruitment for the global Phase 3 study later this year.
• Continue screening and enrolling adolescent participants from the PK run-in study and new FA patients into the open label study.
• Enroll children (2 to 11 years of age) directly into the open label study.
• Submit a Biologics License Application (BLA) seeking accelerated approval in the second quarter of 2026.
• Plan for U.S. launch of nomlabofusp in early 2027.

Key Dates

Recommendation

Larimar Therapeutics is demonstrating strong execution on its nomlabofusp program, which is positioned as the first potential disease-modifying therapy for Friedreich's ataxia, a rare disease with significant unmet medical need. The company has secured clear regulatory guidance from the FDA for accelerated approval, including the acceptance of a novel surrogate endpoint, significantly de-risking the regulatory pathway. Upcoming clinical data readouts in September 2025 are key catalysts that could further validate the drug's efficacy and safety. Furthermore, the recent capital raise has substantially strengthened the balance sheet, providing a cash runway into Q4 2026, which is crucial for funding ongoing clinical trials and BLA preparation. While the company is still incurring losses, this is typical for a clinical-stage biotech nearing commercialization. The combination of a clear regulatory path, promising clinical progress, and robust financial health makes Larimar Therapeutics a compelling investment opportunity.

Keywords

Friedreich's ataxia, nomlabofusp, CTI-1601, rare disease, biotechnology, clinical trial, FDA, accelerated approval, frataxin, FXN, BLA, Phase 3, Q2 2025 earnings, cash runway, orphan drug, protein replacement therapy